1245 related articles for article (PubMed ID: 19752335)
1. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
[TBL] [Abstract][Full Text] [Related]
2. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J
J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000
[TBL] [Abstract][Full Text] [Related]
3. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
[TBL] [Abstract][Full Text] [Related]
4. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
5. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
[TBL] [Abstract][Full Text] [Related]
8. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
9. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
[TBL] [Abstract][Full Text] [Related]
10. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
Corbacioglu A; Scholl C; Schlenk RF; Eiwen K; Du J; Bullinger L; Fröhling S; Reimer P; Rummel M; Derigs HG; Nachbaur D; Krauter J; Ganser A; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(23):3724-9. PubMed ID: 20625124
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia.
Barragán E; Cervera J; Bolufer P; Ballester S; Martín G; Fernández P; Collado R; Sayas MJ; Sanz MA
Haematologica; 2004 Aug; 89(8):926-33. PubMed ID: 15339675
[TBL] [Abstract][Full Text] [Related]
13. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia.
Rodrigues PC; Oliveira SN; Viana MB; Matsuda EI; Nowill AE; Brandalise SR; Yunes JA
Pediatr Blood Cancer; 2007 Aug; 49(2):133-8. PubMed ID: 16883592
[TBL] [Abstract][Full Text] [Related]
15. Quantitative real-time RT-PCR detects elevated Wilms tumor gene (WT1) expression in autologous blood stem cell preparations (PBSCs) from acute myeloid leukemia (AML) patients indicating contamination with leukemic blasts.
Siehl JM; Thiel E; Leben R; Reinwald M; Knauf W; Menssen HD
Bone Marrow Transplant; 2002 Mar; 29(5):379-81. PubMed ID: 11919726
[TBL] [Abstract][Full Text] [Related]
16. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy.
Cilloni D; Messa F; Arruga F; Defilippi I; Gottardi E; Fava M; Carturan S; Catalano R; Bracco E; Messa E; Nicoli P; Diverio D; Sanz MA; Martinelli G; Lo-Coco F; Saglio G
Haematologica; 2008 Jun; 93(6):921-4. PubMed ID: 18443273
[TBL] [Abstract][Full Text] [Related]
17. [Significance of monitoring WT1 mRNA levels of peripheral blood and bone marrow in acute myeloid leukemia].
Kitamura K; Nakano Y; Watamoto K; Koga D; Naoe T
Rinsho Ketsueki; 2010 Dec; 51(12):1748-55. PubMed ID: 21258184
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Schoch C; Haferlach T; Schnittger S
Crit Rev Oncol Hematol; 2005 Nov; 56(2):283-309. PubMed ID: 16213150
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
